Home > Investor Relations > Reports & Downloads > Development Pipeline

Development Pipeline

Oncology

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
AF802/RG7853
(CH5424802/
RO5424802)
Non-small cell lung cancer (NSCLC) Launched
(14/09)
alectinib
Alecensa®
Oral
In-house

(Roche)
ALK inhibitor
Phase III
Overseas
RG7204
(RO5185426)
Melanoma Filed
(14/04)
vemurafenib

Oral
Roche
Zelboraf®
BRAF inhibitor
RG1273
(RO4368451)
Breast cancer (adjuvant) # Phase III
Multinational study
pertuzumab
Perjeta®
Injection
Roche
Perjeta®
HER2 dimerization inhibitory humanized monoclonal antibody
Gastric cancer # Phase III
Multinational study
RG3502
(RO5304020)
Breast cancer (adjuvant) # Phase III
Multinational study
trastuzumab emtansine
Kadcyla®
Injection
Roche
Kadcyla®
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
Gastric cancer # Phase II / III
Multinational study
GA101/RG7159
(RO5072759)
Indolent non-Hodgkin’s lymphoma (NHL) Phase III
Multinational study
obinutuzumab
 
Injection
Roche
Gazyva®/
Gazyvaro® (EU)
(Nippon Shinyaku)
Glycoengineered type II anti-CD20 monoclonal antibody
Aggressive NHL Phase III
Multinational study
RG7446
(MPDL3280A)
NSCLC Phase III
Multinational study


Injection
Roche Engineered anti-PDL1 monoclonal antibody
GC33/RG7686
(GC33/
RO5137382)
Hepatocellular carcinoma Phase II
Multinational study
 
 
Injection
In-house

(Roche)
Anti-Glypican-3 humanized monoclonal antibody
RG340
(Ro09-1978)
Gastric cancer (adjuvant) # Phase II capecitabine
Xeloda®
Oral
Roche
Xeloda®
(Yakult Honsha)
Antimetabolite, 5-FU derivative
CKI27/RG7304
(RO5126766)
Solid tumors Phase I

Oral
In-house

(Roche)
Raf and MEK dual inhibitor
Phase I
Overseas
RG7321
(GDC-0941)
Solid tumors Phase I pictilisib

Oral
Roche PI3K inhibitor
RG7596
(RO5541077)
NHL Phase I polatuzumab vedotin
 
Injection
Roche Anti-CD79b antibody-drug conjugate
RG7604
(GDC-0032)
Solid tumors Phase I taselisib
 
Oral
Roche PI3K inhibitor

Bone and Joint Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG484
(Ro200-5450po)
Osteoporosis Phase III ibandronic acid
Bonviva®
Oral
Roche
Boniva®/
Bonviva® (US)
(Taisho Pharmaceutical)
Bisphosphonate
NRD101
(NRD101)
Enthesopathy
(Lateral epicondylitis, Patellar tendinitis,
Achilles tendinopathy, Plantar fasciitis) #
Development
Discontinued
hyaluronic acid
Suvenyl®
Injection
In-house Hyaluronic acid

Autoimmune Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
MRA
(RO4877533)
Rheumatoid arthritis (new formulation: subcutaneous injection) Approved
(14/04)
EU
tocilizumab
Actemra®
Injection
In-house
Actemra®/
RoActemra® (EU)
(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Large-vessel vasculitis # Phase III
Giant cell arteritis # Phase III
Overseas
Systemic sclerosis # Phase II
Overseas
SA237
(SA237)
Neuromyelitis optica (NMO) Phase III
Multinational study*


Injection
In-house Anti-IL-6 receptor humanized monoclonal antibody

* Multinational study managed by Chugai

Central Nervous System

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1450
(RO4909832)
Alzheimer’s disease Phase III
Multinational study
gantenerumab

Injection
Roche/
MorphoSys
Anti-amyloid-beta human monoclonal antibody
RG7090
(RO4917523)
Major depressive disorder Phase II
Multinational study
basimglurant

Oral
Roche mGluR5 antagonist
RG1577
(RO4602522)
Alzheimer’s disease Phase I

Oral
Roche MAO-B inhibitor
RG1662
(RO5186582)
Improvement of intellectual ability in individuals with Down syndrome Phase I

Oral
Roche GABAAα5 receptor antagonist
RG1678
(RO4917838)
Schizophrenia Development
Discontinued
bitopertin

Oral
Roche Glycine reuptake inhibitor

Respiratory Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG3637
(RO5490255)
Asthma Phase III
Multinational study
lebrikizumab
 
Injection
Roche Anti-IL-13 humanized monoclonal antibody

Others

Development code
(Compound number)
Indication
# Additional
indication
Stage
(Date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
CIM331
(CIM331)
Atopic dermatitis Phase II
Multinational study*
 
 
Injection
In-house Anti-IL-31 receptor humanized monoclonal antibody
URC102
(URC102)
Gout Phase II
Overseas
 
 
Oral
In-house/
JW Pharmaceutical

(JW Pharmaceutical)
URAT1 inhibitor
ACE910/RG6013
(ACE910)
Hemophilia A Phase I / II  
 
Injection
In-house

(Roche)
Anti-factor IXa × anti-factor X humanized bispecific antibody

* Multinational study managed by Chugai

To view PDF files,
you will need Adobe® Reader® which is available as a free download.